Neurology Diagnostics’ Role in Advancing Alzheimer’s Research: LUCIDITY Phase 3 Outcomes
We are pleased to announce advancements in Alzheimer’s Disease research, stemming from the Phase 3 LUCIDITY trial!
Neurology Diagnostics Digest - September 28, 2023
New Referral Process
We are excited to announce that we have a new referral upload form available for your convenience. You can now easily refer your patients to us by faxing over the attached form. We understand that many practices prefer to share referrals via fax or within your EMR (search: Neurology Diagnostics or Dr.Vandersluis) and we welcome those methods as well. Our goal is to make the referral process as seamless and efficient as possible, so please do not hesitate to reach out to us if you have any questions or feedback. The referral sheet is attached and available for download here.
Accepting New Patients
We are currently accepting new patients for general neurology services. Our experienced team provides comprehensive evaluations and treatments for a wide range of neurological conditions. If you have patients who would benefit from our expertise, we would be honored to provide them with the highest level of care.
Services include (but not limited to):
- Gate Disorder/ Falls
- Tremor
- Paresthesias
- Cognitive Impairment
- Neuropathy
- Syncope
- And More
FDA Approves Leqembi, Expanding Alzheimer's Treatment With Contributions from Neurology Diagnostics
We are thrilled to share that the FDA has granted approval for Leqembi, a groundbreaking drug that offers new hope for Alzheimer's patients. Leqembi is an antibody that targets amyloid in the brain, in order to slow the progress of Alzheimer’s. This approval is a significant achievement, particularly for our clinic, Neurology Diagnostics has extensive experience working with anti-amyloid therapies, having enrolled patients in clinical trials here in Dayton, OH since 2018. We look forward to continuing to guide our patients in determining the best options in the assessment and treatment of memory disorders. Read more.
NDX Research Corner
We are actively seeking participants who are impacted by MCI, Alzheimer’s Disease as well as MS. If you have patients who may be a fit, please reach out or refer them to Neurology Diagnostics.
In the near future, we have exciting studies planned, concentrating on Alzheimer's Disease, Chronic Traumatic Encephalopathy (CTE), and Parkinson's Disease. If you're interested in delving deeper into these studies, please feel free to reach out to us for more information.
You Might Also Enjoy...
FDA Approves Leqembi, Expanding Alzheimer's Treatment, with Contributions from Neurology Diagnostics
We are thrilled to share that the FDA has granted approval for Leqembi, a groundbreaking drug that offers new hope for Alzheimer's patients. Leqembi is an antibody that targets amyloid in the brain, in order to slow the progress of Alzheimer’s.
Neurology Diagnostics (NDx) Contributes to Lilly's Alzheimer's Clinical Trial Success
Neurology Diagnostics (NDx) is proud to have been selected for Lilly's ALZ 2 Trailblazer trial and has been seeing patients in this trial since July 2020. As part of the study, NDx has randomized 39 patients of the trial's >1700 patients
New Test Offers Early Parkinson's Disease Detection: A Promising Step Forward in Parkinson's Awarene
A new study in The Lancet Neurology has brought hope to both researchers and patients, as it presents a novel way to test for Parkinson's disease even before any symptoms show up.
Parkinson's Disease Clinical Trial
Parkinson's disease afflicts over one million people in the United States causing a decline in motor skills and cognition due to the destruction of dopamine producing neurons in the brain. Current research targets dopamine receptors in the brain.
Alzheimer's Phase 2 Clinical Trial Success
Neurology Diagnostics is proud to announce our participation and enrollment of patients in the Eli Lilly Alzheimer's disease study recently reported in the New York Times.